HAIFA, Israel, May 7, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that on May 12 it will hold a symposium on therapeutic angiogenesis for Peripheral Arterial Occlusive Disease (PAOD) at the European Society for Vascular Medicine in Berlin, Germany. The symposium, supported by Pluristem, will include presentations and discussions on therapeutic angiogenesis for peripheral arterial occlusive disease. Esther Lukasiewicz Hagai, M.D., Vice President Medical & Clinical Affairs, and Racheli Ofir, Ph.D., Vice President Research & Intellectual Property, will each present. Dr. Lukasiewicz Hagai's presentation is titled "Therapeutic Angiogenesis for Peripheral Arterial Occlusive Disease". Dr. Ofir will present "PLX-PAD Cells: Overview of Pre-clinical Studies in CLI".
Pluristem is currently conducting a Phase II trial for the treatment of intermittent claudication, a type of PAOD. The trial is ongoing in Germany, the U.S., Israel and South Korea. Pluristem has applied to the European Union's accelerated regulatory Adaptive Pathway to conduct a Phase II trial for critical limb ischemia, another form of PAOD.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company's patented PLX (PLacental eXpanded) cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cells are grown using the Company's proprietary three-dimensional expansion technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.
Pluristem has a strong intellectual property position, Company-owned, GMP-certified manufacturing and research facilities, strategic relationships with major research institutions, and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.